Introduction {#Sec1}
============

The major complication of osteoporosis is the clinical manifestation of a hip fracture. Based upon global trends and demographic changes the worldwide number of hip fractures is expected to be over 7.3 million patients in the year 2050 \[[@CR1], [@CR2]\]. In The Netherlands the number of patients sustaining a hip fracture has more than doubled since 1981 to almost 19,000 patients in 2012 \[[@CR3]\]. Almost 60 % of all proximal femoral fractures concern the femoral neck and 80 % of these fractures are displaced \[[@CR4]\]. The Garden classification is frequently used for describing femoral neck fractures in the elderly \[[@CR5]\]. Garden type 3 and 4 represent displaced fractures. Femoral neck fractures can be treated using a non-operative approach, internal fixation, or arthroplasty. The arthroplasty group includes hemiarthroplasty and total hip arthroplasty. Approximately 62 % of patients aged 65 years or older are primarily treated with arthroplasty; hemiarthroplasty is performed in this group in 78 % of patients on average \[[@CR6]\]. Different insights into the preferred treatment of femoral neck fractures are the subject of ongoing international debate \[[@CR7]\]. An international survey revealed that 75 % of the responding surgeons prefer primary arthroplasty for patients over 60 years of age with a displaced fracture. For patients under 60 years of age with a displaced fracture (Garden type 3 or 4), hemiarthroplasty was preferred by 11 % and 25 % of respondents, respectively \[[@CR7]\]. Although initial costs for arthroplasty are higher than for internal fixation, arthroplasty has been proven to be a cost-effective therapy \[[@CR8]--[@CR11]\].

According to data of the Dutch Ministry of Health, Welfare and Sports, hip fracture-associated crude total cost in The Netherlands was €471.5 million in 2011 \[[@CR12]\]. Insight into health care use and associated costs is gaining importance as the burden of health care costs threatens to exceed the financial resources available. Such insight may reveal options for cutting down health care expenses. Although surgeons are expected to have a general idea about the costs for treatments they provide, these data are not easily available \[[@CR13]--[@CR15]\]. Recently, data became available on the total medical costs of femoral neck fracture patients treated with internal fixation in The Netherlands \[[@CR16]\]. To the best of our knowledge, detailed analysis of the costs of hemi- or total hip arthroplasty for femoral neck fractures in The Netherlands has not been published before. Therefore, the aim of this study was to provide a detailed overview of the costs consumed by patients with a displaced femoral neck fracture that was treated with hemi- or total hip arthroplasty.

Patients and methods {#Sec2}
====================

This cost study was conducted as a cohort study alongside the Dutch sample of the HEALTH trial (hip fracture evaluation with alternatives of total hip arthroplasty versus hemiarthroplasty, NCT00556842), an international randomized controlled trial comparing total hip arthroplasty and hemiarthroplasty on revision surgery and quality of life in patients with a displaced femoral neck fracture. The local medical research ethics committees of all participating centers approved the study. Informed consent was obtained from all individual participants included in the study.

Population {#Sec3}
==========

In The Netherlands, 14 hospitals participated and enrolled 150 patients between December 15, 2008 and February 14, 2011. Patients were eligible if they: (1) were adults aged ≥50 years, (2) had a (radiologically confirmed) displaced femoral neck fracture (ICD-10 code S72.0; Garden type 3 and 4) after a low energy impact and no other major trauma, (3) were operated within 3 days of presenting to the emergency room, and (4) were ambulatory pre-fracture (with or without aid). Patients provided informed consent. Patients were excluded if they: (1) were not suitable for treatment with arthroplasty (i.e., inflammatory arthritis, rheumatoid arthritis, pathologic fracture, or severe osteoarthritis of the hip), (2) had infection or retained hardware around the affected hip, (3) had a bone metabolism disorder other than osteoporosis, (4) were moderately or severely cognitively impaired pre-fracture, (5) had dementia or Parkinson's disease severe enough to compromise the rehabilitation process, or (6) were not likely to be able to complete follow-up.

Treatment and follow-up {#Sec4}
-----------------------

Medical optimization was warranted for all included patients before surgery. Within 72 h after presenting to the emergency department, patients were treated with hemi- or total hip arthroplasty. The exact treatment including material choice (cemented or uncemented and unipolar or bipolar prosthesis) was left to the treating surgeon. Antibiotic prophylaxis and thromboprophylaxis were prescribed to all patients according to local protocols. Post-operative weight bearing was as tolerated and early mobilization was encouraged. All patients were screened and treated for osteoporosis if deemed necessary. Follow-up measurements were performed at 10 weeks and at 6, 9, 12, 18, and 24 months after the primary surgery.

Cost measurement {#Sec5}
----------------

This study included the following categories for hip-related costs: (1) hospital costs during primary hospital stay, including emergency department visit, diagnostic evaluations, surgery, and admission days; (2) hospital costs during follow-up, including diagnostic evaluations, outpatient clinic visits, diagnosis and treatment of adverse events, revision surgery, and admission days; and (3) non-hospital costs of rehabilitation and aids.

Data on health care use were collected prospectively at each scheduled follow-up contact and at the close-out visit at the end of the study. Data were collected from the study case report forms (items are listed in electronic supplementary material (ESM) Supplemental Table [1](#MOESM1){ref-type="media"}) and from the patient's hospital file. At each follow-up contact, patients were asked to complete a questionnaire on their health care use. This questionnaire was a customized version of the "Trimbos and iMTA questionnaire on Costs associated with Psychiatric illness" (Tic-P), which has been validated for use in health care cost studies \[[@CR16], [@CR17]\]. An English version of the TicP questionnaire is available online \[[@CR18]\]. The questionnaire included questions on stay in a hospital, rehabilitation center or nursing facility, number of contacts with an intramural medical specialist or paramedical worker during admission and follow-up, medication use, comorbidity and use of walking aids. Missing data were collected during the close-out visit at each hospital.

The total number of consumption units per cost category was multiplied by the unit prices. All unit prices were indexed with the national consumer price index to 2012 and are presented in Table [1](#Tab1){ref-type="table"}. Costs for the index surgery, including time spent in the operating room, theater personnel, overhead, anesthesia, and implant material and general equipment, was provided by two teaching hospitals and one academic hospital. Data from the teaching hospitals were averaged in order to obtain a realistic estimate of the average prices in the participating teaching hospitals. Reference cost prices of most other health care resources were derived from the Dutch manual on cost research, methods and standard costs in economic health care evaluations \[[@CR19]\]. The NZa (Nederlandse Zorgautoriteit; Dutch Health care Authority) is the Dutch market regulator in care and advises the Minister on health care costs. This institute provided the unit prices for intramural diagnostic procedures. Costs of medication were derived from the CVZ (College voor zorgverzekeringen; Health Care Insurance Board), which is online accessible on [www.medicijnkosten.nl](http://www.medicijnkosten.nl/). Costs of rehabilitation aids were obtained from a local home care firm that is a representation of national practice. Costs of aids were calculated according to the annuity method, applying an interest rate of 4.5 % and a 10-year write-off period. With over 90 % of the patients in the study being retired, the costs for production losses were considered of limited importance for this population, and were thus excluded. Home care was also excluded, since it was impossible to determine which proportion of the total home care received was due to the hip fracture. As done previously in a similar study on internal fixation of femoral neck fractures, costs of osteoporosis screening were included in radiology/diagnostic studies costs, costs of visits to an osteoporosis specialist were included in outpatient clinic-visit costs, and costs for osteoporosis treatment were included in medication costs.Table 1Sources and unit costs of health care resourcesCost categoriesUnitSource of consumption dataSource of valueUnit price (€)Hospital costs---primary stay Emergency department visitVisitHospital registryCost manual^a^160.34 Radiology/diagnostic modalities  X-rayX-rayHospital registryNZa^b^54.14  CT-scan pelvisCT-scanHospital registryNZa^b^238.25  MRI scan pelvisMRI scanHospital registryNZa^b^274.16  UltrasoundUltrasoundHospital registryNZa^b^86.07  DEXA scanDEXA scanHospital registryNZa^b^114.52  Skeletal scintigraphyScintigraphyHospital registryNZa^b^194.37 Surgery  SurgeonHourStudy registry (CRF)Cost manual^a^143.88^c^/109.37^d^  Operating room^e^HourStudy registry (CRF)Hospital/industry data^f^738.60^c^/885.00^d^ Equipment and implant  Cemented hemiarthroplastyOperationStudy registry (CRF)Hospital/industry data^f^1362.00^c^/1197.73^d^  Cemented total hip arthroplastyOperationStudy registry (CRF)Hospital/industry data^f^1465.75^c^/1684.45^d^  Uncemented total hip arthroplastyOperationStudy registry (CRF)Hospital/industry data^f^NA/2041.80^d^ Admission daysDayStudy registry (CRF)Cost manual^a^610.57^c^/461.91^d^Hospital costs---follow-up Radiology/diagnostic modalitiesAs described above Outpatient clinic visitsVisitHospital registry + questionnaire^g^Cost manual^a^136.98^c^/67.96^d^ Adverse events  Medication^h^Dose per dayHospital registry/questionnaire^g^CVZ^i^Variable  EmergencyVisitHospital registryCost manual^a^160.34  BracePieceHospital registry/questionnaire^g^Hospital/industry data^f^440.39 Admission daysDayStudy registry (CRF)Cost manual^a^610.57^c^/461.91^d^ Revision surgery  SurgeonHourStudy registry (CRF)Cost manual^a^143.88^c^/109.37^d^  Operating room^e^HourStudy registry (CRF)Hospital/industry data^f^738.60^c^/885.00^d^ Equipment and implant  Cemented hemiarthroplastyOperationsStudy registry (CRF)Hospital/industry data^f^1362.00^c^/1197.73^d^  Cemented total hip arthroplastyOperationsStudy registry (CRF)Hospital/industry data^f^1465.75^c^/1684.45^d^  Uncemented total hip arthroplastyOperationsStudy registry (CRF)Hospital/industry data^f^NA/2041.80^d^  Cup revisionOperationsStudy registry (CRF)Hospital/industry data^f^773.09  Open fenestration/bursectomyOperationsStudy registry (CRF)Hospital/industry data^f^524.20  Open reduction (OR)OperationsStudy registry (CRF)Hospital/industry data^f^333.96  Closed reduction (ER)OperationsStudy registry (CRF)Hospital/industry data^f^160.34  Antibiotic beadsOperationsStudy registry (CRF)Hospital/industry data^f^324.83  Admission daysDaysStudy registry (CRF)Hospital/industry data^f^610.57^c^/461.91^d^ Medication^j^Dose per dayHospital registry/questionnaire^g^CVZ^i^NACosts related to rehabilitation/changes in living situation Rehabilitation center/nursing home  Elderly homeDaysPatient questionnaire^g^Cost manual^a^95.57  Nursing homeDaysPatient questionnaire^g^Cost manual^a^252.73  Rehabilitation clinicDaysPatient questionnaire^g^Cost manual^a^361.04  Home nursing dayDaysPatient questionnaire^g^Cost manual^a^46.72  Physical therapy (outpatient)HourPatient questionnaire^g^Cost manual^a^  Physical therapySessionPatient questionnaire^g^Cost manual^a^38.23 Use of aids  CrutchesDayPatient questionnaire^g^Home care firm^k^0.07  WalkerDayPatient questionnaire^g^Home care firm^k^0.08--0.15  WheelchairDayPatient questionnaire^g^Home care firm^k^0.27  Electric scooterDayPatient questionnaire^g^Home care firm^k^0.70  Extra bedDayPatient questionnaire^g^Home care firm^k^1.22  Extra toilet facilitiesDayPatient questionnaire^g^Home care firm^k^0.10--0.20  Extra shower facilitiesDayPatient questionnaire^g^Home care firm^k^0.10--0.18Reference unit costs anno 2012 were used, or costs were adjusted to 2012 costs by using the national consumer price index*NA* not applicable^a^Cost manual---manual on cost research, methods and standard costs in economic health care evaluations, version 2010 \[[@CR16]\]^b^NZa; Nederlandse Zorgautoriteit (Dutch Health care Authority) standard costs^c^Academic hospital^d^General hospital^e^Including operating room personnel, anesthesia, and overhead costs^f^Hospital/industry data; costs were requested from one academic hospital, three regional hospitals, and one surgical equipment and implant firm. Means were calculated and used as an estimation of the real costs in all participating sites^g^Patient questionnaire---customized version of the "Trimbos and iMTA questionnaire on costs associated with psychiatric illness" \[[@CR17]\]^h^Mainly antibiotics and in-hospital thrombosis profylaxis^i^CVZ---standard prices were used as described by the CVZ (College voor zorgverzekeringen; Health Care Insurance Board), online available on [www.medicijnkosten.nl](http://www.medicijnkosten.nl/)^j^Hip fracture-related medication only (i.e., pain medication and anti-osteoporosis medication; see ESM Supplemental Table [2](#MOESM2){ref-type="media"} for details)^k^Home care firm; costs of aids were requested from a home care firm and costs per day were calculated based on the calculated daily annuity. These costs were used as an estimation of the real costs in all participating patients

Statistical analysis {#Sec6}
--------------------

Data were analyzed using SPSS (version 20.0, SPSS Inc., Chicago, IL, USA). Replacement of missing values for cost items was done with multiple imputations following the predictive mean matching method, using ten imputations \[[@CR20]\]. The following variables were included in the imputation model: sex, age, ASA at baseline, walking independently at baseline, treatment, costs of initial surgery, and all other cost categories at 10 weeks and at 6, 9, 12, 18, and 24 months. Each of the ten complete datasets were further analyzed by non-parametric bootstrapping using 1000 bootstraps per dataset \[[@CR21]\]. The 95 % confidence interval around the mean costs was determined by taking the 2.5th and the 97.5th percentile of these bootstrap replications. Costs were calculated for the total study population.

Results {#Sec7}
=======

Demographics {#Sec8}
------------

The 14 participating hospitals registered 592 consecutive patients with a femoral neck fracture, of whom 181 were eligible and 150 (25 %) subsequently gave informed consent (Fig. [1](#Fig1){ref-type="fig"}). One patient withdrew consent immediately, one patient died before surgery, and seven patients were treated with internal fixation rather than arthroplasty. A total of 141 patients remained for the current cost analysis, of whom 74 were treated with hemiarthroplasty and 67 with a total hip arthroplasty. The mean age was 81 (SD 7; range 57--100) years, 2 patients (1 %; both females) were younger than 60 years of age. A total of 96 patients (68 %) were female. The mean age was 80 (SD 8; range 57--100) years for females and 81 (SD 6; range 69--91) years for males. No patients (0 %) had ASA class 1 or class 5, 67 (48 %) patients had ASA class 2, 72 (51 %) ASA class 3, and 2 (1 %) ASA class 4. A total of 136 (97 %) patients were not institutionalized before the fracture, and 102 (72 %) patients were independently ambulatory before the fracture.Fig. 1Flow-chart of patient enrollment process. \*Patients could meet more than one exclusion criterion

Clinical outcome and health care consumption {#Sec9}
--------------------------------------------

The mean duration of hospital admission was 10 days (SD 8). One patient with a complicated clinical course was discharged at 90 days after the initial surgery. Within 14 days after surgery, 87 % (*N* = 123) of the patients were discharged. The discharge destination was a rehabilitation or nursing facility in 56 % of patients, and 44 % of patients went to their own house. Median stay per patient was 10 days (SD 28) in a rehabilitation facility, 14 days (SD 42) in a nursing facility, and 18 days (SD 62) in an elderly home. During rehabilitation, patients had a mean of 52 (SD 5) physical therapy sessions per patient.

A total of 118 adverse events (AEs) occurred; 77 patients (55 %) had no AE at all. The most frequent AEs were a subsequent fracture (*N* = 19; 13 %), a superficial wound infection (*N* = 11; 8 %), and dislocations (*N* = 10; 7 %). Less than ten patients had other AEs including pulmonary embolism, myocardial infarction, cerebral vascular accident, pneumonia, urinary tract infection, delirium, or decubitus. Eighteen revision surgeries were performed in ten patients (Table [2](#Tab2){ref-type="table"}). Dislocation was treated ten times; seven closed reductions were done in the emergency department, two in the operating room. One patient underwent an open reduction. Three conversions from hemiarthroplasty to total hip arthroplasty were performed. One patient suffered three dislocations after the conversion. One patient underwent an arthrotomy and joint lavage three times to treat a deep infection. One periprosthetic fracture was treated with plating. The 10-week mortality was 5 % (*N* = 7), the 1-year mortality was 11 % (*N* = 16), and the 2-year mortality was 19 % (N = 27). Patients died mainly due to cancer (*N* = 9), cardiovascular diseases (*N* = 6), neurological diseases (*N* = 3), and the bone cement implantation syndrome (*N* = 2). The mean duration of follow-up was 22 months (SD 9).Table 2List of revision surgeries performedRevision surgery 1Revision surgery 2Revision surgery 3Revision surgery 4Patient 1Conversion to THAClosed reduction EDClosed reduction EDClosed reduction EDPatient 2Arthrotomy and joint lavageArthrotomy and joint lavageArthrotomy and joint lavagePatient 3Closed reduction EDClosed reduction EDPlate fixation periprosthetic frxPatient 4Closed reduction ORClosed reduction EDPatient 5Conversion to THAPatient 6Open reductionPatient 7Closed reduction EDPatient 8ArthrotomyPatient 9Conversion to THAPatient 10Closed reduction OR*THA*, total hip arthroplasty; *ED*, emergency department; *OR*, operating room

Costs {#Sec10}
-----

ESM Supplemental Table [3](#MOESM3){ref-type="media"} shows the fraction of patients who used health care and the volume of health care use per user. These data were not imputed. Table [3](#Tab3){ref-type="table"} shows the calculated mean costs for used health care after multiple imputations of the missing data. The overall percentage of missing data was 17.8 % and the relative efficiency of the multiple imputations was 0.98. In the first 10 weeks after the fracture the mean total costs was €15,216, which was 58 % of the total costs. The most important cost category was primary hospital stay accounting for €9026. From this category, costs were predominantly related to hospital admission (€5732) and index surgery (€2915). Other important costs were incurred for rehabilitation facilities and nursing homes (€4707).Table 3Mean costs of femoral neck fracture patients treated with hemi- or total hip arthroplasty (*N* = 141)Cost categoriesCost until 10 weeks (€)Costs until 1 year (€)Costs until 2 years (€)A) Hospital costs---primary stay Emergency department visit160 (160--160)160 (160--160)160 (160--160) Radiology/diagnostic modalities219 (206--232)219 (206--232)219 (206--232) Surgery2,915 (2,798--3,023)2,915 (2,798--3,023)2,915 (2,798--3,023) Admission days5,732 (4,452--7,966)5,732 (4.452--7,966)5,732 (4,452--7,966) Total9,026 (7,706--11,295)9,026 (7,706--11,295)9,026 (7,706--11,295)B) Hospital costs---follow-up Radiology/diagnostic modalities115 (103--128)240 (212--270)344 (278--427) Outpatient clinic visits120 (109--133)297 (263--336)416 (355--494) Adverse events200 (66--392)581 (280--1,056)1,052 (568--1,781) Revision surgery396 (61--990)480 (112--1,100)980 (345--1,940) Medication82 (74--92)106 (93--121)151 (125--182) Total914 (499--1,541)1,705 (1,102--2,563)2,943 (1,894--4,308)C) Costs related to rehabilitation/changes in living situation Rehabilitation center/nursing home4,707 (3,627--5,874)11,694 (8,132--16,350)12,240 (8,542--17,008) Physical therapy (outpatient)549 (470--640)1,340 (1,162--1,537)1,975 (1,627--2,370) Use of aids20 (17--25)105 (78--139)214 (166--270) Total5,276 (4,200--6,467)13,138 (9,486--17,956)14,429 (10,461--19,552)D) Total costs15,216 (13,051--18,323)23,869 (19,157--30,136)26,399 (21,101--33,213)Costs are presented as mean costs at each follow-up moment with 95 % uncertainty interval between bracketsThe data have been imputed. If a patient had not consumed health care, costs for that item were recorded as €0

At 1 year of follow-up, the mean total costs per patient was €23,869 (95 % CI €19,157--€30,136), this was 90 % of the overall total costs. Fifty-five percent of costs were spent on rehabilitation and changes in living situation with a total amount of €13,138. Rehabilitation centers/nursing homes (€11,694) and physical therapy at the outpatient clinic (€1340) were the main cost determinants. After 2 years of follow-up, the total rehabilitation-related costs (€14,429) still accounted for 55 % of the total costs. The hospital costs for follow-up almost doubled from €1705 (7 % of the total costs) after 1 year to €2943 (11 %) after 2 years of follow-up. The main items were costs related to adverse events which increased by 181 % from €581 to €1052 and a 204 % increase in costs for revision surgery from €480 to €980 (Fig. [2](#Fig2){ref-type="fig"}).Fig. 2Relative contribution of costs categories to the total treatment costs of patients until 2 years of follow-up

Discussion {#Sec11}
==========

The mean total costs per patient after treatment with hemi- or total hip arthroplasty for femoral neck fracture were €23,869 (95 % CI €19,157--€30,136) at 1 year and €26,399 (95 % CI €21,101--€33,213) at 2 years after a fracture.

These costs are in line with the range of €12,952 to €43,671 (as adjusted to 2012) found in literature \[[@CR8]--[@CR10], [@CR22]--[@CR27]\]. This broad range can be explained by different variables used in the studies. All studies were performed in western countries, but with different health care systems, mean length of hospital stay, reference costs, and rehabilitation facilities. The populations studied had a relatively small sample size ranging from 32 to 180 patients. One study, involving 19,808 patients, used a Markov decision model \[[@CR22]\]. Although most of the costs are generated in the first year, the two studies with the lowest costs had a follow-up of 1 year \[[@CR23], [@CR25]\], not taking into consideration the late and costly complications. One study \[[@CR9]\] did not include treatment with hemiarthroplasty and two studies only reviewed the costs for patients treated with hemiarthroplasty \[[@CR23], [@CR24]\]. Also, previous studies used different types of costs e.g., in-hospital costs only \[[@CR8]\], the included populations differed in age, or included only women \[[@CR25]\]. Results of the current study correspond best with the results of the two largest studies (adjusted costs €29,834 and €29,807, respectively), both including both types of arthroplasty \[[@CR10], [@CR22]\].

In addition, from a prospective cohort study of 10,275 Dutch persons, the estimated incremental costs of medical care were \$9540 (adjusted to € in 2012: €11,715) in the first year after a hip fracture and \$1017 (€1248) in the subsequent year \[[@CR28]\]. These incremental costs are comparable with the €14,844 (first year) and €2529 (subsequent year) found in the current study. De Laet et al. \[[@CR28]\] found higher costs, but that study did not include detailed costs of adverse events, revision surgeries, and costs of diagnostic modalities. The in-depth method of our study can be considered more specific as the total costs are presented in more detail.

Recently, a similar study was published involving Dutch elderly patients with a femoral neck fracture (50 years or older) who were primarily treated with internal fixation \[[@CR16]\]. Both studies had the same design and used identical research methods, questionnaires, statistics, and resources, making it suitable for direct comparison. After two years of follow-up the costs, adjusted to 2012 for the total internal fixation group were €20,368 (original data: €19,425; 95 % CI €5,237--€58,874). The relative contributions of the different cost categories were very comparable with respect to rehabilitation (46 % of total costs for arthroplasty and 49 % for internal fixation) and hospital admission days (both 22 %), with higher absolute costs in the current arthroplasty study. These differences can be explained by the generally older population in the arthroplasty group based on baseline characteristics. In the current study, the mean age was 10 years older (81 versus 71), patients were more often ASA 3--4 (54 versus 13 %), used aids pre-fracture more often (28 versus 13 %), and had a displaced fracture more often (100 versus 46 %). It is likely that older patients are admitted to a rehabilitation facility more often longer. Moreover, the mean number of hospital admission days (10 versus 7 days) was longer in the arthroplasty group. Subgroup analysis of 67 patients (27 %) who underwent revision to arthroplasty after primary internal fixation resulted in adjusted costs of: €28,031 (€26,733; 95 % CI €9465--€80,029), which exceeds the costs of primary arthroplasty. This emphasizes the need to carefully select primary treatment for hip fractures as conversion from internal fixation to arthroplasty is even more costly than primary arthroplasty.

This study had some limitations. First, the population has been selected, based upon the eligibility for arthroplasty. Therefore it is a specific subset of the total population which presented to the emergency department of the participating hospitals. The patients were relatively healthy, fit, and most were independent walkers before the fracture. Patients with dementia or Parkinson's disease were excluded, but these patients represent a substantial part of the general hip fracture population. These patients may have complex needs and incur higher costs, consequently leading to an underestimation of the mean costs presented. Costs are based on Dutch prices and may vary depending on the health care system used. However, by comparing with published costs from other Western countries, we showed that the results are applicable to other settings as well. Secondly, the actual costs are expected to be even higher as costs for pre-hospital care, costs for routine blood analysis at the emergency department and wards, and perioperative consultation by other medical specialists and, although not routinely applied, forensic autopsy were not included. On the other hand, the number of visits for follow-up and X-rays are lower in general practice than in a trial setting. Also, the amounts used in the cost price manuals used may differ from the actual costs. However, these costs are not expected to be substantial. Finally, costs for home care and general practitioner (GP) visits were not included as for most patients it was impossible to discriminate which part of the post-fracture home care and GP visits was actually due to the hip fracture and not due to care for other pre- or post-fracture conditions. With these limitations in mind the results of the current study are in line with previous international publications.

In conclusion, the treatment of displaced femoral neck fractures with hemi- or total hip arthroplasty is costly with mean total costs after one year of €23,869 and €26,399 after 2 years of follow-up. Rehabilitation and nursing homes account for almost half of the total medical costs, revision surgery, and adverse events not even 10 %. Focus on improvements of the rehabilitation phase can result in reducing costs.
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